title: Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.
abstract: BACKGROUND
  The role of interferon treatment on the natural history of hepatitis C virus related cirrhosis is under debate.
  
  
  OBJECTIVE
  To evaluate the effect of interferon on the clinical course of compensated hepatitis C virus related cirrhosis.
  
  
  METHODS
  Seventy two cirrhotic patients treated with interferon and 72 untreated controls matched treated patients with for quinquennia of age, sex, and Child-Pugh's score were enrolled in a prospective non-randomised controlled trial. Treated patients received leucocytic interferon alfa, with an escalating schedule for 12 months. The incidence and risk (Cox regression analysis) of clinical complications (hepatocellular carcinoma, ascites, jaundice, variceal bleeding, and encephalopathy) and death were calculated.
  
  
  RESULTS
  Over median follow up periods of 55 months for treated and 58 for untreated subjects, seven and nine patients, respectively, died, and 20 and 32, respectively, developed at least one clinical complication (ns). Hepatocellular carcinoma developed in six treated and 19 untreated patients (p=0.018). Seven treated patients showed sustained aminotranferase normalisation and none died or developed complications. Clinical complications were significantly associated with low albumin, bilirubin, and prothrombin activity while hepatocellular carcinoma was significantly related to no treatment with interferon, oesophageal varices, and high alpha fetoprotein levels. By stratified analysis, the beneficial effect of interferon was statistically evident only in patients with baseline alpha fetoprotein levels > or =20 ng/ml.
  
  
  CONCLUSIONS
  Interferon does not seem to affect overall or event free survival of patients with hepatitis C virus related cirrhosis while it seems to prevent the development of hepatocellular carcinoma. Patients who achieved sustained aminotransferase normalisation survived and did not develop any complications during follow up.
authors.affiliation: Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Università di Bologna, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Gramenzi
authors.forename: P
authors.initials: P
authors.lastname: Andreone
authors.forename: S
authors.initials: S
authors.lastname: Fiorino
authors.forename: C
authors.initials: C
authors.lastname: Cammà
authors.forename: M
authors.initials: M
authors.lastname: Giunta
authors.forename: D
authors.initials: D
authors.lastname: Magalotti
authors.forename: C
authors.initials: C
authors.lastname: Cursaro
authors.forename: C
authors.initials: C
authors.lastname: Calabrese
authors.forename: V
authors.initials: V
authors.lastname: Arienti
authors.forename: C
authors.initials: C
authors.lastname: Rossi
authors.forename: G
authors.initials: G
authors.lastname: Di Febo
authors.forename: M
authors.initials: M
authors.lastname: Zoli
authors.forename: A
authors.initials: A
authors.lastname: Craxì
authors.forename: G
authors.initials: G
authors.lastname: Gasbarrini
authors.forename: M
authors.initials: M
authors.lastname: Bernardi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000821:virology; D018572:Disease-Free Survival; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D008113:Liver Neoplasms / Q000097:blood / Q000821:virology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012044:Regression Analysis; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D000509:alpha-Fetoproteins